Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 8 de 8
Filter
Add more filters










Database
Language
Publication year range
1.
Hum Vaccin Immunother ; 18(2): 1886560, 2022 04 29.
Article in English | MEDLINE | ID: mdl-34010089

ABSTRACT

Passive immunization with polyclonal hyper immunoglobulin (HIG) therapy represents a proven strategy by transferring immunoglobulins to patients to confer immediate protection against a range of pathogens including infectious agents and toxins. Distinct from active immunization, the protection is passive and the immunoglobulins will clear from the system; therefore, administration of an effective dose must be maintained for prophylaxis or treatment until a natural adaptive immune response is mounted or the pathogen/agent is cleared. The current review provides an overview of this technology, key considerations to address different pathogens, and suggested improvements. The review will reflect on key learnings from development of HIGs in the response to public health threats due to Zika, influenza, and severe acute respiratory syndrome coronavirus 2.


Subject(s)
COVID-19 , Zika Virus Infection , Zika Virus , Antibodies , COVID-19/prevention & control , Humans , Immunization, Passive , Immunoglobulins/therapeutic use , SARS-CoV-2
2.
PLoS One ; 11(6): e0157970, 2016.
Article in English | MEDLINE | ID: mdl-27336843

ABSTRACT

Clostridium difficile (C. difficile) infection (CDI) is the main cause of nosocomial antibiotic-associated colitis and increased incidence of community-associated diarrhea in industrialized countries. At present, the primary treatment of CDI is antibiotic administration, which is effective but often associated with recurrence, especially in the elderly. Pathogenic strains produce enterotoxin, toxin A (TcdA), and cytotoxin, toxin B (TcdB), which are necessary for C. difficile induced diarrhea and gut pathological changes. Administration of anti-toxin antibodies provides an alternative approach to treat CDI, and has shown promising results in preclinical and clinical studies. In the current study, several humanized anti-TcdA and anti-TcdB monoclonal antibodies were generated and their protective potency was characterized in a hamster infection model. The humanized anti-TcdA (CANmAbA4) and anti-TcdB (CANmAbB4 and CANmAbB1) antibodies showed broad spectrum in vitro neutralization of toxins from clinical strains and neutralization in a mouse toxin challenge model. Moreover, co-administration of humanized antibodies (CANmAbA4 and CANmAbB4 cocktail) provided a high level of protection in a dose dependent manner (85% versus 57% survival at day 22 for 50 mg/kg and 20 mg/kg doses, respectively) in a hamster gastrointestinal infection (GI) model. This study describes the protective effects conferred by novel neutralizing anti-toxin monoclonal antibodies against C. difficile toxins and their potential as therapeutic agents in treating CDI.


Subject(s)
Antibodies, Bacterial , Antibodies, Monoclonal, Humanized , Antibodies, Monoclonal/immunology , Antibodies, Neutralizing , Antitoxins/immunology , Bacterial Proteins/immunology , Bacterial Toxins/immunology , Enterotoxins/immunology , Neutralization Tests , Animals , Clostridioides difficile/immunology , Clostridioides difficile/isolation & purification , Clostridium Infections/immunology , Clostridium Infections/microbiology , Clostridium Infections/mortality , Cricetinae , Disease Models, Animal , Humans , Immunoglobulin G/immunology , Mice , Spores, Bacterial
3.
Adv Hematol ; 2016: 7678901, 2016.
Article in English | MEDLINE | ID: mdl-26997955

ABSTRACT

The goal of these studies was to extensively characterize the first recombinant FIX therapeutic corresponding to the threonine-148 (Thr-148) polymorph, IXINITY (trenonacog alfa [coagulation factor IX (recombinant)]). Gel electrophoresis, circular dichroism, and gel filtration were used to determine purity and confirm structure. Chromatographic and mass spectrometry techniques were used to identify and quantify posttranslational modifications. Activity was assessed as the ability to activate factor X (FX) both with and without factor VIIIa (FVIIIa) and in a standard clotting assay. All results were consistent across multiple lots. Trenonacog alfa migrated as a single band on Coomassie-stained gels; activity assays were normal and showed <0.002 IU of activated factor IX (FIXa) per IU of FIX. The molecule has >97% γ-carboxylation and underwent the appropriate structural change upon binding calcium ions. Trenonacog alfa was activated normally with factor XIa (FXIa); once activated it bound to FVIIIa and FXa. When activated to FIXa, it was inhibited efficiently by antithrombin. Glycosylation patterns were similar to plasma-derived FIX with sialic acid content consistent with the literature reports of good pharmacokinetic performance. These studies have shown that trenonacog alfa is a highly pure product with a primary sequence and posttranslational modifications consistent with the common Thr-148 polymorphism of plasma-derived FIX.

4.
J Microbiol Methods ; 101: 49-55, 2014 Jun.
Article in English | MEDLINE | ID: mdl-24726869

ABSTRACT

Pseudomonas aeruginosa establishes chronic infections by forming biofilms; however studies of the virulence have focused on the planktonic form. Few in vitro co-culture models exist to study biofilm infections. We present a novel in vitro co-culture method examining the interactions between mature P. aeruginosa biofilms and human lung epithelial cells.


Subject(s)
Biofilms/growth & development , Coculture Techniques/methods , Plankton/physiology , Respiratory Mucosa/cytology , Respiratory Mucosa/microbiology , Apoptosis , Bacterial Adhesion , Humans , Interleukin-8 , Models, Biological
5.
Antimicrob Agents Chemother ; 56(9): 4976-9, 2012 Sep.
Article in English | MEDLINE | ID: mdl-22777043

ABSTRACT

Phenotypic tolerances to antibiotics of mature and young Pseudomonas aeruginosa PAO1 biofilms and released planktonic bacteria were compared for four antibiotics. Resistance levels were similar for gentamicin and ciprofloxacin but differed for ceftazidime and meropenem. ß-Lactamase mapping showed that, after 5 h of ceftazidime exposure, mature biofilms produced more ß-lactamase than young biofilms, facilitating the growth of released planktonic bacteria. This shows the importance of early treatment and choice of antibiotics for P. aeruginosa biofilm infections.


Subject(s)
Anti-Bacterial Agents/pharmacology , Biofilms/drug effects , Ceftazidime/pharmacology , Ciprofloxacin/pharmacology , Gentamicins/pharmacology , Pseudomonas aeruginosa/drug effects , Thienamycins/pharmacology , Biofilms/growth & development , Drug Resistance, Multiple, Bacterial/drug effects , Gene Expression/drug effects , Meropenem , Microbial Sensitivity Tests , Plankton/drug effects , Plankton/growth & development , Pseudomonas aeruginosa/enzymology , Pseudomonas aeruginosa/genetics , Time Factors , beta-Lactamases/genetics , beta-Lactamases/metabolism
6.
Am J Physiol Heart Circ Physiol ; 301(3): H746-56, 2011 Sep.
Article in English | MEDLINE | ID: mdl-21622819

ABSTRACT

Angiotensin receptor antagonists have shown clinical promise in modulating vascular disease, in part by limiting smooth muscle cell proliferation and migration. The majority of studies examining the contribution of these receptors have been undertaken in cells derived from rat aorta, which primarily express the ANG II type 1 (AT(1)) receptor. This investigation studied the relative contribution of AT(1) and ANG II type 2 (AT(2)) receptors to the mitogenic program of porcine smooth muscle cells. Smooth muscle cells were derived from porcine coronary artery explants. The presence of both AT(1) and AT(2) receptors was demonstrated through ligand binding and RT-PCR analysis. Biochemical and cellular markers of proliferation were monitored in the presence of selective receptor antagonists. Smooth muscle cell migration was measured using both wound healing and Boyden chamber migration assays. Visualization of the AT(1) and AT(2) receptors in growing and quiescent porcine smooth muscle cells with epifluorescence microscopy demonstrated that their subcellular distribution varied with growth state. An examination with several growth assays revealed that both AT(1)-specific losartan and AT(2)-specific PD-123319 receptor antagonists inhibited ANG II-stimulated RNA and DNA synthesis, PCNA expression, and hyperplasia. ANG II induced both directional and nondirectional cell migration. AT(1) receptor antagonist treatment significantly decreased ANG II-induced directional migration only, whereas AT(2) receptor antagonist treatment significantly reduced both modes of migration. Interestingly, the focal adhesion kinase inhibitor PF-573228 also blocked migration but not proliferation. Furthermore, focal adhesion kinase activation in response to ANG II was prevented only by PD-123319, indicating that this activation is downstream of the AT(2) receptor. The observed role of the AT(2) receptor in ANG II-induced migration was confirmed with smooth muscle cells depleted of the AT(2) receptor with short hairpin RNA treatment.


Subject(s)
Cell Movement , Cell Proliferation , Muscle, Smooth, Vascular/metabolism , Myocytes, Smooth Muscle/metabolism , Receptor, Angiotensin, Type 1/metabolism , Receptor, Angiotensin, Type 2/metabolism , Angiotensin II/metabolism , Angiotensin II Type 1 Receptor Blockers/pharmacology , Angiotensin II Type 2 Receptor Blockers/pharmacology , Animals , Cell Movement/drug effects , Cell Proliferation/drug effects , Cells, Cultured , Coronary Vessels/metabolism , Dose-Response Relationship, Drug , Focal Adhesion Protein-Tyrosine Kinases/antagonists & inhibitors , Focal Adhesion Protein-Tyrosine Kinases/metabolism , Imidazoles/pharmacology , Losartan/pharmacology , Muscle, Smooth, Vascular/drug effects , Myocytes, Smooth Muscle/drug effects , Protein Kinase Inhibitors/pharmacology , Pyridines/pharmacology , Quinolones/pharmacology , RNA Interference , Receptor, Angiotensin, Type 1/drug effects , Receptor, Angiotensin, Type 1/genetics , Receptor, Angiotensin, Type 2/drug effects , Receptor, Angiotensin, Type 2/genetics , Reverse Transcriptase Polymerase Chain Reaction , Sulfones/pharmacology , Swine , Time Factors
7.
Infect Immun ; 78(10): 4176-86, 2010 Oct.
Article in English | MEDLINE | ID: mdl-20643855

ABSTRACT

Novel approaches targeting the host's immune response to treat Staphylococcus aureus infections have significant potential to improve clinical outcomes, in particular during infection with antibiotic-resistant strains. The hyaluronic acid-binding peptide (HABP) PEP35 was assessed for its ability to treat S. aureus infections using a clinically relevant murine model of surgical wound infection. PEP35 demonstrated no direct antimicrobial activity against a range of antibiotic-susceptible and antibiotic-resistant clinical isolates of Staphylococcus aureus. However, when this peptide was administered at the onset of infection and up to 4 h postchallenge with a methicillin-susceptible (MSSA) or a methicillin-resistant (MRSA) strain of S. aureus, it significantly reduced the bacterial burden at the wound infection site. PEP35 reduced the tissue bacterial burden by exclusively modulating the local neutrophil response. PEP35 administration resulted in a significant early increase in local CXCL1 and CXCL2 production, which resulted in a more rapid influx of neutrophils to the infection site. Importantly, neutrophil influx was not sustained after treatment with PEP35, and administration of PEP35 alone did not induce a local inflammatory response. The immunomodulatory effects of PEP35 on CXC chemokine production were TLR2 and NF-κB dependent. We propose a novel role for a HABP as an innate immunomodulator in the treatment of MSSA and MRSA surgical wound infection through enhancement of the local CXC chemokine-driven neutrophil response.


Subject(s)
Hyaluronan Receptors/pharmacology , Neutrophils/drug effects , Neutrophils/physiology , Staphylococcal Infections/drug therapy , Wound Infection/drug therapy , Animals , Cell Line , Chemokines, CXC/metabolism , Humans , Hyaluronan Receptors/metabolism , Immunologic Factors/pharmacology , Methicillin-Resistant Staphylococcus aureus/physiology , Mice , Mice, Inbred C57BL , Mice, Knockout , NF-kappa B/metabolism , Staphylococcal Infections/microbiology , Toll-Like Receptor 2/genetics , Toll-Like Receptor 2/metabolism , Wound Healing/drug effects , Wound Infection/microbiology
8.
J Pharmacol Exp Ther ; 326(3): 717-24, 2008 Sep.
Article in English | MEDLINE | ID: mdl-18523160

ABSTRACT

The association of ADP-ribosylation with cell proliferation and ischemia-reperfusion injury suggests that it may be a suitable target for therapeutic control of revascularization-induced injury. The purpose of this study was to investigate the inhibitory actions of ADP-ribosylation inhibitors on restenosis. In organ culture, the poly(ADP-ribose) polymerase (PARP) inhibitor 3,4-dihydro-5-methylisoquinolinone (PD128763) was unable to prevent neointimal hyperplasia, whereas the arginine-dependent mono(ADP-ribosyl)transferase (ART) inhibitor meta-iodobenzylguanidine (MIBG) was highly effective (EC(50) 21 microM). Treatment with 3-aminobenzamide (3AB), a less potent ART inhibitor, also produced a significant reduction in neointimal hyperplasia. Single doses (25 mM) of MIBG and 3AB were also applied within a fibrin coagulum directly to the adventitial surface of the porcine femoral artery after balloon catheter injury in vivo. MIBG reduced the neointimal index, measured 14 days after angioplasty, by 82%, whereas 3AB was ineffective. However, when extended to 45 days, the neointimal index was not significantly decreased by MIBG treatment relative to control. Assessment of MIBG release from the fibrin glue showed that the bulk of the compound was eluted within 3 days, suggesting that the vehicle was not suitable for long-term delivery. On the other hand, direct infusion of MIBG into vessels was able to reduce neointimal hyperplasia over 14 days in organ culture. These data support the conclusion that the cellular retention characteristics of MIBG contribute significantly to the efficacy of this compound. Based on these results, ART, but not PARP, may be a credible target for therapeutic treatment of restenosis.


Subject(s)
3-Iodobenzylguanidine/pharmacology , ADP Ribose Transferases/antagonists & inhibitors , Arginine/antagonists & inhibitors , Tunica Intima/drug effects , Tunica Intima/pathology , 3-Iodobenzylguanidine/therapeutic use , ADP Ribose Transferases/metabolism , Animals , Arginine/physiology , Enzyme Inhibitors/pharmacology , Hyperplasia/prevention & control , Male , Organ Culture Techniques , Swine , Tunica Intima/enzymology
SELECTION OF CITATIONS
SEARCH DETAIL
...